EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 19 September 2019

On innovation, patient-centricity and added value

On innovation, patient-centricity and added value
18 September 2019

From time to time we see an article or a headline on the theme that "so and so many new drugs have no added value". The latest example was an article published in the BMJ in July, looking at assessments done by the German agency IQWiG between 2011 and 2017. It says that more than half of the new drugs that have entered the German health system lacks proof of an added value.

It sounds outrageous, and when you start to think about it also rather mysterious, almost baffling. Who approved all these drugs that have no added value? Why were they developed? What kind of doctor prescribes them, and what kind of patient takes them? Or are they all sitting on a shelf somewhere, produced en masse by a soon to be bankrupt pharmaceutical company who made a bad investment decision? Read more

News

93 European Associations call for an Ambitious Horizon Europe Programme
16 September 2019

We are fully convinced that Europe has the potential to lead the global innovation race and to remain a model of economic... Read more

Blogs

EFPIA is ready to answer the EU’s call for action on antimicrobial resistance
19 September 2019 - Nathalie Moll

The new European Commission President-elect has made antimicrobial resistance (AMR) a priority – we are working with... Read more

Videos

Connecting Healthcare
With the challenges facing healthcare in Europe, no one sector has all the answers. It is only by working together that... Read more

Children keep us up at night
And #WeWontRest until we’ve helped make the world a healthier place for every single one of them Read more

Events

Europe at the forefront of global healthcare regulation
30 September 2019 (Dublin)

TOPRA Symposium 2019 Read more

War on Cancer 2019
26 November 2019 (London)

Celebrating success, accelerating progress Read more

Regenerative Medicine: Scientific Advances and Regulatory Framework in Europe
27 November 2019 (Brussels)

The aim of this workshop is to provide a comprehensive overview on scientific advances, ongoing clinical trials, regulatory... Read more

Science, Technology and Regulations Coming Together for Better Patients’ Health
10 February 2020 (Amsterdam)

The primary objective of the Conference is to ensure that all attendees are brought fully up to date with the current... Read more

We published

Driving Health and Growth; A call for an industrial strategy for Europe
10 September 2019 (Publications)

Five areas where policy makers can take action to drive Europe’s health and growth Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu